Novel PNPT1-ALK Fusion Variant Exerted Significant Benefit to Crizotinib in NSCLC

The frequency of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) is approximately 3% to 5% [1], and the administration of ALK tyrosine kinase inhibitors has achieved impressive outcomes. Apart from EML4 –ALK, various ALK fusion partner genes have recently been identified [2]. In this case, we report a novel PNPT1 (polyribonucleotide nucleotidyl transferase 1)–ALK fusion responding to crizotinib in a patient with lung adenocarcinoma.

Source: Lung Cancer - May 14, 2020 Category: Cancer & Oncology Authors: Linling Jin, Yanli Wang, Si Li, Dongsheng Chen, Xin Zhao Source Type: research